The global hybrid imaging market size was valued at USD 6.9 billion in 2018 and is anticipated to register a CAGR of 4.5% over the forecast period. Government initiatives for the development of multimodal or hybrid diagnostic imaging devices is expected to drive the market. For instance, European Cooperation in Science and Technology (COST), a government-funded organization that helps in creating research networks referred to as COST actions has started a program called Correlated Multimodal Imaging in Life Sciences (COMULIS). This initiative aims to promote Correlated Multimodal Imaging (CMI) in preclinical and biological research. This COST action will be implemented for four years, thereby boosting the adoption of multimodal imaging technology.
A significant number of hospitals, research centers, and research institutes are frequently installing hybrid imaging devices to assess their potential in various applications, a move that has kept market growth steady in recent years. In July 2019, West Virginia University (WVU) Heart and Vascular Institute installed the Alphenix 4D CT machine by Canon Medical Systems. By installing this, the hospital upgraded its interventional radiology equipment for the diagnosis and treatment of heart disease, vascular disease, and cancer. Moreover, this device is infused with multiple diagnostic modalities with various clinical applications, which in turn helps in delivering holistic and optimized patient information to healthcare professionals. Similarly, in August 2019, Kawasaki Medical University, Japan installed the E-Class U-SPECT6/CT for preclinical imaging.
Usage of hybrid imaging in diagnosis of diseases across various disciplines of medicine, including oncology, cardiology, and neurology, has been on a steep rise in recent years. This is resulting into growing demand for skilled professionals for capturing and understanding the data collected by these devices. Therefore, various institutes and research centers are conducting training programs for multimodal imaging. The European School of Radiology (ESOR) has organized the Exchange Programme for Hybrid Imaging Fellowship with the support of the European Society for Hybrid, Molecular and Translational Imaging (ESHIMT) and European Society of Radiology (ESR). This program will provide modular training in SPECT/CT, PET/CT, and PET/MR and will facilitate learning about radiochemistry production of traces and image data processing. Such training programs are going to expose trainees to various aspects of multimodal imaging.
Multimodal imaging devices face major technological challenges due to complications pertaining to system integration. For instance, a conventional PET system requires PMTs for the detection of scintillation light and PMTs are highly sensitive to magnetic fields. Therefore, a standard PET cannot be directly operated inside an MRI machine. In order to avoid this issue, PET and MR require separation via active shield to protect PMTs against the magnetic fields, thereafter integrated device can be used for medical imaging. This could act as a deterrent to multimodal/hybrid imaging market growth.
Based on type, the market is segmented into PET/CT systems, SPET/CT systems, PET/MR systems, OCT/Fundus imaging, and others. PET/CT systems held the largest market share in 2018 primarily due to its growing usage in the field of oncology. Moreover, its usage is expanding in the field of cardiology and neurology. In addition, the penetration of PET/CT hybrid imaging device over standalone PET is increasing, which in turn, is contributing to segment growth. For instance, U.S. has the highest concentration of about four PET and PET/CT units per million inhabitants, followed by Japan with approximately two units per million inhabitants.
The SPET/CT segment is expected to grow at the fastest pace during the forecast period. Standalone SPET devices were widely used for nuclear medicine; however, data captured by the standalone device was not sufficient to provide accurate anatomic localization of the abnormality. SPECT integrated with other imaging devices such as CT results in better diagnosis of a disease as it helps in effectively determining the morphological abnormality and pathogenesis of the disease. This hybrid imaging device is mainly used for the diagnosis of cardiac diseases.
The OCT/Fundus Imaging System segment is also expected to grow at a significant pace over the coming years. This multimodal imaging device is mainly used in the field of ophthalmology for clinical and preclinical procedures. Fundus camera increases the visibility of retinal vasculature, pigmentation, nerve fiber arrangement, and optic nerve head. On the other hand, OCT helps in capturing a defined image to measure the inner and outer thickness of the retina, thereby enhancing the diagnosis of ophthalmic disorders.
Based on application, the hybrid imaging systems market is segmented into oncology, ophthalmology, cardiology, brain and neurology, and others. Oncology held the largest share in 2018 due to increasing number of cancer cases. As per the National Cancer Institute, in 2018, approximately 1,735,350 new cancer cases were diagnosed in the U.S. alone. Various imaging modalities are used for the diagnosis, staging, re-staging, treatment, and monitoring of cancer. Standalone devices such as CT, MRI, PET, and SPECT help in providing anatomical and functional detail of the cancer; however, they lack in providing insights about tumor morphology. Therefore, various hybrid imaging devices such as PET/CT, SPET/CT, and PET/MR are being effectively used in the field of oncology to gather accurate data for proper diagnosis. This is expected to boost segment growth during the forecast period.
The cardiology segment is expected to grow at the fastest pace during the forecast period mainly due to increasing prevalence of coronary atherosclerosis and adoption of multimodal imaging for diagnosis. These devices, mainly computed tomography coronary angiography (CTCA) with SPECT or PET, are largely used in the field of cardiology. This is because these multimodal devices help in diagnosing coronary artery disease by accurately visualizing coronary atherosclerotic lesions and their hemodynamic consequences. CTCA along with MRI and PET/MRI are upcoming hybrid imaging devices for the diagnosis of cardiac diseases and are expected to drive the segment during the forecast period.
The brain and neurology segment is also expected to grow at a lucrative through 2026. Dual modality imaging devices such as PET/MRI are effectively used for the detection of neurological disorders such as dementia, epilepsy, and psychiatric disorders. This combined modality device helps in effective diagnosis of neurological disorders as it can generate soft tissue contrast of brain tissue, without excessive exposure to radiation.
Based on end use, the multimodal imaging market is segmented into hospitals, diagnostic centers, and others. Others include research centers and academies. Hospitals held the largest market share in 2018 mainly due to increasing installation of multimodal imaging devices in hospitals. Presence of trained medical professionals to operate technologically advanced devices such as these is also expected to boost segment growth.
Diagnostic centers are expected to grow at the fastest pace during the forecast period. Growing demand for diagnosis of various diseases in the field of oncology, cardiology, neurology, and others is leading to development of separate diagnostic centers with advanced devices. Many medical practitioners as well as professionals are developing their own diagnostic centers to meet the increasing demand for diagnosis, thereby driving the adoption of hybrid imaging devices in these centers.
Research centers and academies are frequently installing multimodal imaging devices to train medical practitioners regarding the usage of the device and to conduct preclinical research. For instance, in September 2018, Huntsman Cancer Institute installed the nanoScan PET/MRI 3T by Mediso, to advance its cancer imaging techniques. Through the installation of this device, the institute hopes to diagnose a wide range of rodent tumor models, which in turn, will help in testing novel cancer therapies with defined images.
North America held 24.0% of the global hybrid imaging systems market in 2018. Growing prevalence of cancer and cardiovascular diseases in the region is expected to boost market growth. Growing awareness regarding this technology in the U.S. and increasing training programs for the same is also expected to contribute toward the growth of this regional market. In the U.S., radiology residents have to complete one year of fellowship to fulfil the eligibility criteria of the American Board of Radiology. Under this fellowship, residents need to be certified in nuclear radiology, which involves nuclear imaging, radiopharmaceuticals usage, and quality control of nuclear imaging instruments. Such growing initiatives are expected to boost the market in North America.
Europe accounted for the second largest share in the hybrid imaging market. Growing focus on developing multimodal imaging in the region is expected to drive the market in Europe. The European Society for Hybrid, Molecular and Translational Imaging (ESHIᴹᵀ) is a non-profit organization developed in Europe for promoting and coordinating professional activities of people working in the field of hybrid imaging. This organization arranges various educational and training programs for physicians, scientists, physicists, technologists, radiographers, and others in the field.
Asia Pacific is expected grow at the fastest pace during the forecast period. Growing usage of hybrid devices such as PET/CT in various radiology departments across the region is expected to contribute to market growth. Moreover, global market players are continuously developing advanced software for multimodal imaging devices in the region. For instance, syngo.via by Siemens Healthineers incorporates various technologies such as Pre-fetching, ALPHA Technology, SMART Layout, and Findings Navigator, which helps in translating data captured by various multimodality imaging devices such as PET/CT and SPECT/CT into concise reports.
Leading players present in the market include GE Healthcare; Koninklijke Philips N.V.; Siemens Healthineers; CANON MEDICAL SYSTEMS CORPORATION; Bruker; Mediso Ltd.; MILabs B.V.; MR Solutions; TriFoil Imaging; PerkinElmer Inc.; FUJIFILM VisualSonics Inc.; and Cubresa Inc. These players are focusing on developing multimodal imaging devices for preclinical research, in alliance with suppliers and companies. In addition, in order to increase their product reach, these companies are showcasing their products at various conferences and medical trade shows.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million and CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, The Netherlands, Switzerland, Turkey, Poland, China, India, Japan, Thailand, South Korea, Indonesia, Taiwan, Hong Kong, Philippines, Malaysia, Mexico, Brazil, Chile, Argentina, South Africa, Saudi Arabia, UAE, Iran
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global hybrid imaging market report on the basis of type, application, end use, and region:
Type Outlook (Volume, Units; Revenue, USD Million, 2015 - 2026)
OCT/Fundus Imaging System
Application Outlook (Revenue, USD Million, 2015 - 2026)
Brain & Neurology
End-use Outlook (Revenue, USD Million, 2015 - 2026)
Diagnostic Imaging Centers
Regional Outlook (Revenue, USD Million, 2015 - 2026)
Middle East & Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPA norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The longer incubation period of SARS-CoV is a huge problem for early diagnosis and effective treatment in the ongoing pandemic. PET-CT systems are being used to study lung legions and ground-glass opacities in Covid-19 patients. We are working to account for this surge in our estimates. The updated report will account for Covid-19 as a key market contributor.